SuperB与Zilverpass试验的事后分析:长段复杂股浅动脉病变的治疗
该研究事后合并SuperB与Zilverpass试验的血管内治疗组数据,比较肝素涂层自膨式覆膜支架(Viabahn,SECS)与药物洗脱支架(ZilverPTX,DES)治疗长段复杂股腘动脉病变的1年结局。共纳入176例(SECS组63例,DES组113例),两组1年一期通畅率无显著差异,仅符合方案分析中DES组二期通畅率显著更优,支持对长段复杂股腘动脉病变行血管内治疗。
要点
- 1年一期通畅率SECS组与DES组无显著差异(意向性分析63.4% vs 71.1%,P=.183)。
- 符合方案分析中二期通畅率DES组显著优于SECS组(95.1% vs 85.6%,P=.038)。
- 两组免于靶病变血运重建率无显著差异(79.6% vs 77.0%,P=.481)。
核心结论
- 肝素涂层Viabahn覆膜支架与ZilverPTX药物洗脱支架治疗复杂股腘动脉病变的1年一期通畅率、二期通畅率及靶病变血运重建率相似,但符合方案分析中二期通畅率DES组更优。
- 该研究进一步支持对股腘动脉长段复杂病变行血管内治疗。
研究设计与样本
- SuperB试验与Zilverpass试验的事后分析,合并两试验数据库,纳入血管内治疗组患者。
- 共纳入176例患者,SECS组63例,DES组113例,按意向性治疗和符合方案两种方式分析。
- 主要终点为1年随访时的一期通畅率,次要终点为二期通畅率、靶病变血运重建、肢体丢失和全因死亡。
主要发现
- 1年一期通畅率意向性分析SECS组63.4% vs DES组71.1%(P=.183),符合方案分析SECS组60.8% vs DES组71.1%(P=.100),均无显著差异。
- 1年二期通畅率意向性分析SECS组86.5% vs DES组95.1%(P=.054),无显著差异;符合方案分析SECS组85.6% vs DES组95.1%(P=.038),DES组显著更优。
- 免于靶病变血运重建率SECS组79.6% vs DES组77.0%(P=.481),无显著差异。
- SECS组无大截肢,DES组大截肢2例(1.8%);1年生存率SECS组98.2% vs DES组91.3%(P=.106)。
- 按诊断(间歇性跛行 vs 慢性肢体威胁性缺血)分层,一期通畅率、二期通畅率和免于靶病变血运重建率均无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In two randomized controlled trials, the outcomes of endovascular treatment of complex femoropopliteal arterial lesions were compared with bypass surgery and considered a valid alternative treatment. The aim of this study was to compare both endovascular treatment options with the hypothesis that implantation of heparin-bonded self-expanding covered stents (Viabahn [SECS]) or drug-eluting stents (ZilverPTX [DES]) are related to similar clinical outcomes at 1-year follow-up. METHODS: In a post-hoc analysis, the SuperB trial and Zilverpass databases were merged. Patients in the endovascular treatment arms were included, and data was analyzed in an intention-to-treat (ITT) and a per-protocol (PP) fashion. Data included baseline and lesion characteristics, procedural details, and follow-up data. The primary endpoint of this study was primary patency at 1-year follow-up. The secondary endpoints were secondary patency, target lesion revascularization (TLR), limb loss, and all-cause mortality. RESULTS: A total of 176 patients were included; 63 in the SECS arm and 113 in the DES arm. Through 1-year follow-up, there were no significant differences in primary patency (ITT: 63.4% vs 71.1%: P = .183 and PP: 60.8% vs 71.1%; P = .100). Secondary patency rates were not significantly different in the ITT analysis (86.5% vs 95.1%; P = .054), but in the PP analysis, there was a significant difference in favor of the DES group (SECS, 85.6% vs DES, 95.1%; P = .038). There was no significant difference in freedom from TLR between groups (79.6% vs 77.0%; P = .481). No major amputations were performed in the SECS group, and two were performed in the DES group (1.8%). Survival rate was 98.2% in the SECS group, and 91.3% in the DES group after 1-year follow-up (P = .106). Based on diagnosis (intermittent claudication vs chronic limb-threatening ischemia) no differences between patients with intermittent claudication and chronic limb-threatening ischemia were observed in primary patency, secondary patency and freedom from TLR. CONCLUSIONS: Treatment of complex femoropopliteal arterial disease with the heparin-bonded Viabahn endoprosthesis and the Zilver PTX drug-eluting stent are related to similar primary and secondary patency, and TLR rates at 1 year, except for secondary patency in the PP analysis. This study further supports the endovascular treatment of long complex lesions in the femoropopliteal artery.
引用
- van Walraven LA, Kalil VM, van der Veen D, et al. Post hoc analysis of the SuperB and Zilverpass trials for treatment of long and complex superficial femoral artery lesions. J Vasc Surg. 2024. PMID: 38604319. doi:10.1016/j.jvs.2024.03.449
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。